Boris Freidlin - Publications, H-index & Citations

Boris Freidlin

National Cancer Institute

49H指数

200论文数

1.1W被引数

收录论文 38

发表时间

Two-to-one randomization is associated with increased control-arm patient withdrawal 二比一随机化与对照臂患者退出率增加相关

JNCI: Journal of the National Cancer Institute

IF0

2026-09-30

PREAI

Boris Freidlin, PhD; Edward L Korn, PhD

Changing standard of care during a randomized trial: examples, considerations and guidelines

JNCI: Journal of the National Cancer Institute

IF0

2026-01-24

PREAI

Boris Freidlin, PhD; Malcolm A Smith, MD; Carmen J Allegra, MD; Edward L Korn, PhD

A note on rank-preserving structural failure time models to account for crossover 关于保持秩的结构性失效时间模型以考虑交叉现象的笔记

Clinical Trials

IF2.2

2026-01-01

PREAI

Torres-Saavedra, Pedro A.; Freidlin, Boris; Jeong, Jong-Hyeon; Korn, Edward L.

Backfilling Patients in Phase I Dose Escalation Trials: Do it Safely and Efficiently

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-10-01

PREAI

Yuan, Y.; Korn, E.; Freidlin, B.

Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)

CLINICAL CANCER RESEARCH

IF10.2

2023-12-04

PREAI

Zhao, Yixuan; Yuan, Ying; Korn, Edward L.; Freidlin, Boris

The potential to backfill in phase I trials: the National Cancer Institute's Cancer Therapy Evaluation Program experience

JNCI CANCER SPECTRUM

IF4.1

2023-11-24

OAAI

Foster, Jared C.; Korn, Edward L.; Freidlin, Boris; Moscow, Jeffrey A.

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice 美国国家癌症研究所联合治疗平台试验与治疗选择的分子分析

CLINICAL CANCER RESEARCH

IF10.2

2023-01-20

OAAI

Meric-Bernstam, Funda; Ford, James M.; O'Dwyer, Peter J.; Shapiro, Geoffrey I.; McShane, Lisa M.; Freidlin, Boris; O'Cearbhaill, Roisin E.; George, Suzanne; Glade-Bender, Julia; Lyman, Gary H.; Tricoli, James, V; Patton, David; Hamilton, Stanley R.; Gray, Robert J.; Hawkins, Douglas S.; Ramineni, Bhanumati; Flaherty, Keith T.; Grivas, Petros; Yap, Timothy A.; Berlin, Jordan; Doroshow, James H.; Harris, Lyndsay N.; Moscow, Jeffrey A.

Dose optimization during drug development: whether and when to optimize

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE

IF7.2

2022-12-19

OAAI

Korn, Edward L.; Moscow, Jeffrey A.; Freidlin, Boris

Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE

IF7.2

2022-11-30

OAAI

LoRusso, Patricia M.; Freidlin, Boris

Augmenting randomized clinical trial data with historical control data: Precision medicine applications

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE

IF7.2

2022-09-26

OAAI

Freidlin, Boris; Korn, Edward L.

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

BLOOD CANCER JOURNAL

IF11.6

2022-06-29

OAAI

Kumar, Shaji; Baizer, Lawrence; Callander, Natalie S.; Giralt, Sergio A.; Hillengass, Jens; Freidlin, Boris; Hoering, Antje; Richardson, Paul G.; Schwartz, Elena I.; Reiman, Anthony; Lentzsch, Suzanne; McCarthy, Philip L.; Jagannath, Sundar; Yee, Andrew J.; Little, Richard F.; Raje, Noopur S.

Clinical Benefit Scales and Trial Design: Some Statistical Issues

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE

IF7.2

2022-05-18

OAAI

Korn, Edward L.; Allegra, Carmen J.; Freidlin, Boris

A Problematic Biomarker Trial Design

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE

IF7.2

2021-07-21

OAAI

Freidlin, Boris; Korn, Edward L.